Clinical Trial Update: Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eslicarbazepine acetate (BIA 2-093) for acute manic episodes in Bipolar I disorder; the study was terminated but results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: BIPOLAR I DISORDER | Phase 2 | Status: TERMINATED | Results posted: 2013-09-18